


flawco
presents

RET INNOVATE 2025 PROGRAMME



Sponsors

Main



Supporting





MediNect is a preclinical contract research organisation (CRO) specialising in ophthalmology and translational eye research. Headquartered in Belfast, Northern Ireland, MediNect combines academic depth with commercial agility to

accelerate the development of innovative therapies for retinal diseases.

Our Expertise

MediNect provides a full spectrum of preclinical retinal disease services, including:

- *In vivo* efficacy and pharmacology in:
 - wetAMD
 - dryAMD
 - Inherited Retinal Diseases,
 - Diabetic Macular Oedema
 - Retinopathy of Prematurity
 - Retinal Vein Occlusion
 - Diabetic Retinopathy
 - Subretinal Fibrosis
 - Glaucoma
 - Uveitis (coming in 2026)
- Rodent and Rabbit pharmacokinetic (PK) and pharmacodynamic (PD) assessments across ocular compartments.
- Advanced 2D & 3D *in vitro* retinal and RPE models to complement *in vivo* studies for early screening and mechanistic understanding.
- Integration of mechanistic insights and biomarker discovery to support translational decision-making.
- Zebrafish drug screening (New for 2026)

Facilities and Capabilities

- Specialised laboratories for rodent and rabbit ocular studies.
- State-of-the-art imaging, histology, flow cytometry and molecular biology suites.
- Validated ocular PK/PD workflows supporting formulation and dose optimisation.
- Partnerships providing access to advanced analytical platforms for bioanalysis and multiomics.



Coming 2026



Ask about our special academic rates



MediNect Bioservices Ltd

+44 28 960 05459

www.medinet.co.uk

enquiries@medinet.co.uk





Clinical Translational Research & Innovation Centre



C-TRIC is a state-of-the-art clinical research facility (CRF), and not-for-profit company, located on Altnagelvin Hospital site in Derry/Londonderry. C-TRIC'S specialised staff and facilities provide expert services such as C-TRIC Multiomics and C-TRIC's HTA-licenced Bioresource.

C-TRIC's Bioresource operates under a rigorous quality management system to maintain sample integrity. Our monitoring system, calibrated to UKAS ISO/IEC 17025:2017 standard is supported by a 24/7 response team. We serve both academic and commercial clients, offering flexible storage, comprehensive research support, sample collection, and processing services.

C-TRIC's multiomics facilities enhance clinical research by providing access to high-throughput single-cell multiomics, next generation sequencing (NGS) services and flow cytometry.



Single-cell resolution

Insights into the variation between individual cells within a sample (fruit salad) rather than average from a population of different cells (smoothie). This is essential for understanding disease at a cellular level, allowing precise and more effective therapeutics to be developed.



Multiomic profiling

Simultaneously analysing gene, protein expression and methylation from single cells. It is crucial to take a multiomics approach to better understanding cell biology, including cell differentiation, disease mechanisms, and immune responses.



Applications

Suitable for multiple research applications within eye research, previously applied to various areas of retinal vasculature. Investigation of disease mechanisms to identify biomarkers, therapeutic targets and evaluate impact of therapeutic compounds on cells of interest aiding in the development of precision treatments.

GET IN TOUCH!

028 7161 1249

c-tric.com / info@c-tric.com

Altnagelvin Hospital Campus, Glenshane Road,
Derry/Londonderry BT47 6SB



Schedule

DAY 1 FLOW

THURSDAY 13TH NOVEMBER

8:30AM

**REGISTRATION +
NETWORKING SCENES**

Registration

9:00AM

WELCOME + OPENING

Tunde Peto

Opening remarks from clinical KOL

9:15AM - 9.45AM

INTRO

James Bojdo and Chris McCabe

From Market to Bench. A reverse engineered approach to innovation.

9:15AM

**SESSION 1
PRECLINICAL RESEARCH:
DESIGNING WITH
PURPOSE**

**Alan Stitt, Chair of Ophthalmology, QUB
Kevin Harkin, Head of Ophthalmology, Medinect**
Strategies for ensuring translational relevance from the outset. Model selection, species choice, and study endpoints aligned to the different audiences.

11:00AM

COFFEE BREAK

A chance to network with colleagues and speakers.

11:20 AM

**SESSION 2
PRECLINICAL RESEARCH:
DESIGNING WITH
PURPOSE II**

Tine Van Bergen, OcuRes Consult

A data package for smooth clinical progression:
Designing robust, reproducible studies that meet regulatory and investor expectations. .

12:15 PM

**SESSION 3
REGULATORY PATHWAY
FOR RETINAL
THERAPEUTICS**

Stephen Liggett & Tine Van Bergen

Regulatory routes for retinal disease therapeutics
Key agency expectations, submission strategies, and approval timelines.



**12.45-1.45
LUNCH**

Network with speakers and fellow participants and discuss key innovation challenges.

**1.45-2.45 PM
SESSION 4
INTELLECTUAL PROPERTY**

Tim Belcher, Partner at EIP
IP milestones from discovery to market: Strategies for building defensible, value-driving patent portfolios.

**2.45-3.45PM
SESSION 5
PITCHING PERFECT**

Claire Gelfman, CMG Consulting-Retina Focus - online
Pitching to get Investor attention

**3.45-3.50PM
COFFEE BREAK**

Pick up Coffee

**3.50PM- 4.30PM
SESSION 6
UPS & DOWNS OF
BIOTECH WITH COFFEE**

Andy Osbourne, VP Preclinical, Ikarovec
Diary of an Academic through to Biotech
Informal chat with Q&As about working in a start-up biotech and exiting.


**4.30PM
FIRST DAY WRAP UP**

Session wrap up - heading to the onsite bar

**6:30 PM
DRINKS/DINNER
RECEPTION**



In collaboration with EVICR.net.
Join us for an evening reception with attendees of this years EVICR.net conference to meet clinicians that will play a critical role in your journey to clinic.
MALONE LODGE



DAY 2 FLOW

FRIDAY 14TH NOVEMBER

8:30AM
REFLECTIONS, RECAP
AND REFRESHMENTS

Regroup with participants and speakers

9:00AM
SESSION 1
TARGET PRODUCT
PROFILE WORKSHOP

Tine Van Bergen, Ocures Consult
Exercise: Developing a TPP framework: Target Product Profile as a strategic roadmap: Key components and methods for shaping a competitive product vision.

10:00AM
SESSION 2
INVESTABLE STARTUP

Luis Santana Diaz, LSDH Strategy
The Architecture of an Investable Startup

11:00AM- 11.15AM
COFFEE BREAK

COFFEE BREAK

11:15 AM
SESSION 3
INVESTOR RELATIONS
AND DUE DILLIGENCE

Jaspreet Grewal, Axial Bridge
Insights and expectation from investors

12.15 PM - 12.45PM
FIRESIDE CHAT

Global innovation landscape and investor insights

- **Jaspreet Grewal**, Founder, Axial Bridge
- **Paul Ryb**, Partner, Outcome Capital
- **Alan Stitt**, Editor-in-Chief - Progress in Retinal and Eye Research

12.45PM- 1.45PM
LUNCH

Lunch



1.45 PM - 2.15PM
SESSION 4
MARKET ACCESS I

Chris McCabe
Affordable and sustainable Health Care - A challenge and opportunity for life science innovations.

2.15-3.00 PM
SESSION 5
MARKET ACCESS II

Chris McCabe
Starting with the end in mind - Early Health Technology Assessment and Value-Led Innovation

3.00 PM- 3.45PM
SESSION 6
MARKET ACCESS III

Chris McCabe
Headroom, value based pricing and indication selection

3.45PM - 4.00PM
COFFEE BREAK

COFFEE BREAK

4:00PM- 4.30PM
SESSION 7
MARKET ACCESS IV

Chris McCabe
Unpacking price from the pre-clinical end of the telescope

4:30PM - 5.00PM
SESSION 8
MARKET ACCESS V

Chris McCabe
Uncertainty and risk; research, investment and prices + Recap and Q&A.

5:00PM
FINAL SESSION

Prof. Alan Stitt
What the future holds.
Looking at the the past, oresent and future

5:30 PM NETWORKING



Notes



Notes



Notes



Notes



Notes



Notes



Notes



Notes



Notes



Notes



Notes



Notes



Notes



Notes



Notes



Notes



Notes

Notes



Notes



Notes



Notes



Notes



Notes



Notes



Notes



Notes



Notes



Notes



Notes



Notes



Notes



Brought to you by



Stay informed about

RETINNOVATE 2026

